Company: ENTXW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001178913-25-003852
Chunk: 24

Company: Entera Bio Ltd.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 2
Chunk 24
---
 and development expenses for the three and nine months ended September 30, 2025 and September 30, 2024 are summarized as follows:

  Nine Months Ended September 30,(unaudited)  Three Months Ended September 30,(unaudited) ​ 2025  ​2024  2025  2024 ​ (In thousands)  (In thousands) External Expenses related to EB613 $1,544  $934  $572  $782 Internal and External expenses related to OXM collaboration with OPKO  190   -   70   - Internal and External expenses related to other development program:                      Payroll and related expenses  1,184   1,107   418   372       Share-based compensation  799   643   329   229       Rent and related expenses  344   244   122   62       Other development expenses  255   370   132   32 Research and development expenses, net $4,286  $3,298  $1,643  $1,477 

General and Administrative Expenses

General and administrative expenses consist principally of salaries and related expenses, share-based compensation and related costs for directors and personnel in executive and finance functions. Other general and administrative expenses include D&O insurance and other insurance, communication expenses, professional fees for legal and accounting services, costs associated with maintaining and prosecuting our intellectual property portfolio and business development expenses.

Financial Income, Net

Financial income, net is composed primarily of interest income from bank deposits and exchange rate differences of certain currencies against our functional currency, which is the U.S. Dollar.

Taxes on Income

We have not generated taxable income since our inception, and, as of September 30, 2025, we had carryforward tax losses of $89.8 million.

We anticipate that we will be able to carry forward these tax losses indefinitely to future tax years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carryforward tax losses. We provided a full valuation allowance with respect to the deferred tax assets related to these carryforward losses.

The Company’s subsidiary, Entera Bio, Inc., is taxed separately under U.S. tax laws. As of September 30, 2025, Entera Bio Inc. had